Product Code: GMDHC0434TDB
Summary
Global Markets Direct's, 'Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Review, H2 2016', provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted pipeline therapeutics.
The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)
- The report reviews Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) Overview
- Therapeutics Development
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Stage of Development
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Therapy Area
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Indication
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Products Glance
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Products under Development by Companies
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Therapeutics Assessment
- Assessment by Monotherapy/Combination Products
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Companies Involved in Therapeutics Development
- Alveonix AG
- Dompe Farmaceutici S.p.A.
- Glenmark Pharmaceuticals Ltd.
- RaQualia Pharma Inc.
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Drug Profiles
- AVX-012 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Ax-10 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Ax-8 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DFL-23448 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RQ-00203078 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RQ-00434739 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Antagonize TRPM8 for Neuropathic Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonize TRPM8 for Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Dormant Projects
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for, H2 2016
- Number of Products under Development by Therapy Area, H2 2016
- Number of Products under Development by Indication, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Number of Products under Development by Companies, H2 2016
- Products under Development by Companies, H2 2016
- Assessment by Monotherapy/Combination Products, H2 2016
- Number of Products by Stage and Mechanism of Action, H2 2016
- Number of Products by Stage and Route of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
- Pipeline by Alveonix AG, H2 2016
- Pipeline by Dompe Farmaceutici S.p.A., H2 2016
- Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
- Pipeline by RaQualia Pharma Inc., H2 2016
- Dormant Projects, H2 2016
List of Figures
- Number of Products under Development for, H2 2016
- Number of Products under Development by Therapy Area, H2 2016
- Number of Products under Development by Indication, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy/Combination Products, H2 2016
- Number of Products by Mechanism of Actions, H2 2016
- Number of Products by Stage and Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
